Chester County News and Community Website
NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) has announced the successful completion of Phase I clinical trials for tivoxavir marboxil, an investigational one-dose treatment aimed at combating H5N1 bird flu. …
Traws Pharma Advances Bird Flu Treatment with Successful Phase I Trial Read More
BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) has begun dosing adolescents aged 12-17 in its pediatric pharmacokinetic (PK) run-in study for Friedreich’s ataxia (FA), marking an important step in …
Larimar Therapeutics Initiates Dosing in Pediatric Study for Friedreich’s Ataxia Read More
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) has cemented a collaboration with renowned cell therapy leaders Professors Georg Schett and Andreas Mackensen to initiate a Phase 1/2 trial exploring its …
Century Therapeutics Partners with Experts for New Trial on Autoimmune Diseases Read More
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) unveiled encouraging clinical data for its investigational therapy, VP-315, at the 2025 Winter Clinical Dermatology Conference in Miami, Florida. The Phase 2 …
Verrica Showcases Promising VP-315 Data at Dermatology Conference Read More
MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) this week announced the dosing of the first patient in its Phase 1 clinical trial for OCU200, a potential treatment for diabetic macular edema …
Breakthrough in Sight? Ocugen’s OCU200 Targets Vision Loss for Millions in New Clinical Trial Read More
PHILADELPHIA, PA — Context Therapeutics Inc. (Nasdaq: CNTX has announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76. This experimental treatment is a …
Breakthrough in Cancer Treatment? Context Therapeutics Launches Phase 1 Trial for CLDN6-Targeted Therapy Read More MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has announced a positive 2-year safety and efficacy update from its Phase 1/2 clinical trial for OCU400, a groundbreaking gene therapy targeting retinitis pigmentosa …
Breakthrough in Vision: Ocugen’s OCU400 Shows Promising 2-Year Results for Retinitis Pigmentosa Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently released a draft guidance in collaboration with the Office for Human Research Protections, outlining recommendations for including tissue biopsies in …
FDA Issues Draft Guidance on Tissue Biopsies in Clinical Trials Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has announced positive outcomes from a Phase 2 study evaluating QTORIN™ 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations …
Palvella Therapeutics Reports Promising Results for QTORIN Rapamycin in Treating Rare Genetic Disease Read More
PHILADELPHIA, PA — Passage Bio, Inc. (Nasdaq: PASG) has shared updated findings from its ongoing Phase 1/2 upliFT-D clinical trial, which evaluates PBFT02 as a potential treatment for frontotemporal dementia …
Passage Bio Reports Promising Data in Trial for Frontotemporal Dementia Treatment Read More